Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP0218
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
**SP0218** is a subcutaneous formulation of a prophylactic yellow fever vaccine developed by Sanofi. It is a Vero cell-based vaccine designed to stimulate immune responses against the yellow fever virus, providing protection against this mosquito-borne flaviviral disease prevalent in tropical regions of South America and Africa. The vaccine acts as an **immunostimulant**, inducing both humoral and cellular immunity to prevent yellow fever infection, with ongoing clinical evaluation focused on safety, tolerability, and immunogenicity compared to standard intramuscular formulations.[1][3][5][7]
- Brand names
- vYF
- Other names
- vYF (Sanofi Pasteur)Yellow fever vaccine (Sanofi Pasteur)
Beyond the preview
Go deeper on SP0218.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP0218.